Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, United States.
Cancer Epidemiol. 2013 Oct;37(5):666-70. doi: 10.1016/j.canep.2013.07.005. Epub 2013 Aug 20.
Ecological, in vitro, and in vivo studies demonstrate a link between vitamin D and prostate tumor growth and aggressiveness. The goal of this study was to investigate whether plasma concentration of vitamin D is associated with survivorship and disease progression in men diagnosed with prostate cancer.
We conducted a population-based cohort study of 1476 prostate cancer patients to assess disease recurrence/progression and prostate cancer-specific mortality (PCSM) risks associated with serum levels of 25(OH) vitamin D [25(OH)D].
There were 325 recurrence/progression and 95 PCSM events during an average of 10.8 years of follow-up. Serum levels of 25(OH)D were not associated with risk of recurrence/progression or mortality. Clinically deficient vitamin D levels were associated with an increased risk of death from other causes.
We did not find evidence that serum vitamin D levels measured after diagnosis affect prostate cancer prognosis. Lower levels of vitamin D were associated with risk of non-prostate cancer mortality.
生态学、体外和体内研究表明维生素 D 与前列腺肿瘤的生长和侵袭性之间存在关联。本研究的目的是调查诊断为前列腺癌的男性的血浆维生素 D 浓度是否与生存和疾病进展相关。
我们进行了一项基于人群的队列研究，共纳入 1476 例前列腺癌患者，以评估血清 25（OH）维生素 D [25（OH）D]水平与疾病复发/进展和前列腺癌特异性死亡率（PCSM）风险之间的关系。
在平均 10.8 年的随访期间，发生了 325 例复发/进展和 95 例 PCSM 事件。血清 25（OH）D 水平与复发/进展或死亡率风险无关。临床缺乏维生素 D 水平与其他原因导致的死亡风险增加有关。
我们没有发现诊断后测量的血清维生素 D 水平影响前列腺癌预后的证据。较低的维生素 D 水平与非前列腺癌死亡率的风险相关。
